Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 3/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3360242 | 1.00 | ACKR3 (0.49) | ACKR3OPRL1HRH2HRH1SIGMAR1 | |
| SCHEMBL5676544 | 0.85 | ACKR3 (0.53) | ACKR3OPRL1SIGMAR1ALDH1A1LMNA | |
| SCHEMBL5676548 | 0.85 | ACKR3 (0.53) | ACKR3OPRL1SIGMAR1ALDH1A1LMNA | |
| SCHEMBL3356191 | 0.81 | ACKR3 (0.51) | ACKR3HRH2HRH1 | |
| SCHEMBL3356195 | 0.81 | ACKR3 (0.51) | ACKR3HRH2HRH1 | |
| SCHEMBL13496112 | 0.81 | P2RX7 (0.54) | ACKR3 | |
| SCHEMBL3361016 | 0.80 | ACKR3 (0.46) | ACKR3HRH2HRH1SIGMAR1ALDH1A1 | |
| SCHEMBL7130405 | 0.80 | HDAC8 (0.54) | HRH2HRH1HTTSMN1; SMN2 | |
| SCHEMBL12152878 | 0.79 | CTSS (0.51) | — | |
| SCHEMBL2850833 | 0.76 | KDM1A (0.48) | ACKR3SIGMAR1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100036122-A1 | CLEAVAGE AGENT SELECTIVELY ACTING ON SOLUBLE ASSEMBLY OF AMYLOIDOGENIC PEPTIDE OR PROTEIN | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KP) | 2010-02-11 | — | — | US | disclosed |
| WO-2008051017-A1 | A CLEAVAGE AGENT SELECTIVELY ACTING ON SOLUBLE ASSEMBLY OF AMYLOIDOGENIC PEPTIDE OR PROTEIN | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036122-A1 | CLEAVAGE AGENT SELECTIVELY ACTING ON SOLUBLE ASSEMBLY OF AMYLOIDOGENIC PEPTIDE OR PROTEIN | APP, BACE1, IAPP | ACKR3 2018/4885OPRL1 4258/4885HRH2 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.